PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT
Bleeding, Thrombosis and Vascular Biology · 16.04.2026 · 5 (s1)
DOI: 10.4081/btvb.2026.540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, online erschienen am 16.04.2026. Verfasst von Società Italiana di Emostasi e Trombosi. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Venous thromboembolism (VTE) is a major cardiovascular complication in cancer patients and the leading cause of morbidity and mortality. The study aimed to evaluate the incidence, timing, clinical predictors, and management of VTE in patients with breast cancer (BC) undergoing oncological therapy and to propose a risk-adapted strategy for thrombosis monitoring and prevention.
Methods
In this retrospective single-center study, we included 116 women with histologically confirmed BC (stages I–IV) treated between 2021 and 2024. Patients were divided according to the occurrence of objectively confirmed VTE. Clinical characteristics, comorbidities, laboratory parameters, cancer-related factors, and treatment modalities were analyzed. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of VTE.
Results
VTE occurred in 25 patients (21.6%), predominantly within the first 12 months after cancer diagnosis. Deep vein thrombosis of the lower and upper extremities was the most common manifestation (52%), while pulmonary embolism was present in 24% of cases, either alone or in combination (20%). Patients who developed VTE were significantly older and more frequently had hypertension, dyslipidemia, hyperglycemia, anemia, and leukocytosis. Multivariate analysis identified age ≥55 years (OR 1.74, 95% CI: 1.18 to 2.72), ECOG performance status ≥3 (OR 1.92, 95% CI: 1.29 to 2.12), and elevated glucose level (OR 2.21, 95% CI: 1.53 to 3.14) as independent predictors of VTE. Direct oral anticoagulants were the most frequently used agents of long-term anticoagulant therapy.
Conclusions
VTE is a clinically relevant and relatively frequent complication in patients with BC, particularly during the early period of anticancer treatment. Patient-related and metabolic factors play a key role in thrombosis risk, underscoring the need for individualized, risk-adapted approaches to VTE prevention and monitoring in this cohort.
Zitieren
APA
Trombosi, S. I. D. E. E. (2026). PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT. Bleeding, Thrombosis and Vascular Biology, 5(s1). https://doi.org/10.4081/btvb.2026.540
Vancouver
Trombosi SIDEE. PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT. Bleeding, Thrombosis and Vascular Biology. 2026;5(s1). doi:10.4081/btvb.2026.540
BibTeX
@article{Trombosi2026,
author = {Trombosi, Società Italiana di Emostasi e},
title = {PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
volume = {5},
number = {s1},
doi = {10.4081/btvb.2026.540}
}
EUVIMED